Compare PERI & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PERI | IMRX |
|---|---|---|
| Founded | 1999 | 2008 |
| Country | Israel | United States |
| Employees | N/A | 57 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 346.5M | 232.3M |
| IPO Year | 2005 | 2021 |
| Metric | PERI | IMRX |
|---|---|---|
| Price | $8.72 | $3.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $13.00 | ★ $17.17 |
| AVG Volume (30 Days) | 237.2K | ★ 663.1K |
| Earning Date | 11-11-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.75 | N/A |
| Revenue Next Year | $10.33 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.63 | $3.38 |
| 52 Week High | $11.27 | $8.48 |
| Indicator | PERI | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.09 | 35.41 |
| Support Level | $8.28 | N/A |
| Resistance Level | $9.70 | $5.32 |
| Average True Range (ATR) | 0.24 | 0.18 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 51.91 | 31.18 |
Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.